id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2004-E-0143-0007,FDA,FDA-2004-E-0143,Certificate Extending Patent Term from U.S. Patent and Trademark Office to Eli Lilly and Company,Rule,Certificate Extending Patent Term,2007-04-23T04:00:00Z,2007,4,,,2025-11-12T17:44:00Z,,0,0,090000648046fe53
FDA-2004-E-0143-0006,FDA,FDA-2004-E-0143,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2006-09-07T04:00:00Z,2006,9,,,2025-11-12T17:40:39Z,,0,0,090000648046fe52
FDA-2004-E-0143-0005,FDA,FDA-2004-E-0143,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2006-06-19T04:00:00Z,2006,6,,,2025-11-12T17:36:00Z,,0,0,090000648046fe51
FDA-2004-E-0143-0004,FDA,FDA-2004-E-0143,Determination of Regulatory Review Period for Purposes of Patent Extension; ALIMTA,Notice,General Notice,2006-02-10T05:00:00Z,2006,2,2006-02-08T05:00:00Z,,2025-11-12T17:32:34Z,E6-1642,0,0,090000648046fe50
FDA-2004-E-0143-0003,FDA,FDA-2004-E-0143,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2006-01-11T05:00:00Z,2006,1,,,2025-11-11T01:14:41Z,,0,0,090000648046fe4f
FDA-2004-E-0143-0002,FDA,FDA-2004-E-0143,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-09-02T04:00:00Z,2004,9,,,2025-11-11T01:11:25Z,,0,0,090000648046fe4e
FDA-2004-E-0143-0001,FDA,FDA-2004-E-0143,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2004-07-15T04:00:00Z,2004,7,,,2025-11-11T01:08:21Z,,0,0,090000648046fe4b